[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lutslower-urinary-tract-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lutslower-urinary-tract-symptoms":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100614232","phase-4-perioperative-tamsulosin-for-treating-voiding-dysfunction-following-prostate-biopsy-100614232",false,"NCT07276919","Perioperative Tamsulosin for Treating Voiding Dysfunction Following Prostate Biopsy","Perioperative Tamsulosin for Treating Voiding Dysfunction Following Prostate Biopsy: A Multicenter, Randomized, Controlled, Open-Label Study","Inclusion Criteria:\n\n* Male, aged 40 to 85 years (inclusive).\n* Meets indications for prostate biopsy per clinical guidelines (e.g., suspicious nodule on digital rectal exam, suspicious lesion on imaging, tPSA \\>10 ng\u002FmL, or tPSA 4-10 ng\u002FmL with f\u002Ft \\\u003C0.16 or PSAD \\>0.15).\n* Voluntarily participates and provides written informed consent.\n\nExclusion Criteria:\n\n* Previous prostate surgery, urinary diversion, or intermittent catheterization.\n* Use of alpha-adrenergic blockers (e.g., Tamsulosin, Doxazosin) within one week prior to screening.\n* Known or suspected allergy\u002Fintolerance to Tamsulosin, or history of orthostatic hypotension.\n* Indwelling urinary catheter or suprapubic cystostomy tube at the time of biopsy.\n* History of severe bleeding disorders.\n* Poorly controlled or unstable comorbidities such as hypertension or diabetes.\n* Severe immunosuppression.\n* Severe psychological disorders or uncooperative for the biopsy procedure.\n* Active urinary tract infection or neurogenic bladder.\n* Any other condition deemed by the investigator as unsuitable for participation.","MALE","40 Years","85 Years",{"count":20,"type":21},1844,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to learn if the drug Tamsulosin Hydrochloride works to treat urination difficulties after a prostate biopsy in men.The main questions it aims to answer are:\n\n* Does Tamsulosin Hydrochloride lower the rate of Acute Urinary Retention (inability to urinate) after a prostate biopsy?\n* Does Tamsulosin Hydrochloride improve participants' urination symptoms, quality of life, urine flow rate, and post-void residual urine volume?\n\nResearchers will compare the drug group to a control group (receiving no preventive medication) to see if Tamsulosin Hydrochloride works to prevent urination problems.\n\nParticipants will:\n\n* Be randomly assigned to either take Tamsulosin Hydrochloride or receive no preventive medication.\n* If in the drug group, take one capsule of Tamsulosin Hydrochloride every night, starting 3 days before the biopsy and continuing until 6 days after the biopsy (10 doses total).\n* Undergo a standard prostate biopsy procedure (either through the rectum or perineum).\n* Return to the clinic 7 days after the biopsy for a follow-up checkup, which will include questions about their symptoms (IPSS and QoL scores) and tests to measure urine flow and bladder emptying.",[27,28],"Acute Urinary Retention","LUTS(Lower Urinary Tract Symptoms)",[30,31,32,33],"acute urinary retention","LUTS(Lower urinary tract symptoms)","tamsulosin","prostate biopsy","NOT_YET_RECRUITING","2025-12-20",{"date":37,"type":38},"2025-12-23","ACTUAL",{"date":40,"type":21},"2026-02-01",{"date":42,"type":21},"2028-01-01",{"name":44,"class":45},"Peking University First Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":18,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":46},"100580628","safety-and-efficacy-of-milep-versus-standard-eep-100580628","NCT06839768","Safety and Efficacy of MILEP Versus Standard EEP","The MILES Trial: Prospective Randomized Trial of Safety and Efficacy of Minimally-invasive Versus Standard Laser Enucleation of the Prostate","MILES","Inclusion Criteria:\n\nLUTS presence, proven by:\n\n1. IPSS questionnaire (Score \\>20);\n2. OR uroflowmetry result (Qmax \\\u003C10 ml\u002Fs);\n\nExclusion Criteria:\n\n* Prostate volume \\> 120 cc\n* Prostate cancer on pathology;\n* Urethral strictures;\n* Bladder calculi;\n* Prior prostate surgery;\n* Neurogenic bladder dysfunction.","18 Years",{"count":57,"type":21},340,[59],"NA","Endoscopic enucleation of the prostate (EEP) is a standard treatment for benign prostatic hyperplasia (BPH), with modifications such as MiLEP that utilizes smaller instruments. The reduced resectoscope diameter in MiLEP may help decrease rates of stress urinary incontinence (SUI) and urethral strictures.\n\nObjective: to compare the efficacy and safety of MiLEP and standard EEP with a thulium fiber laser (TFL).",[62,28],"Benign Prostate Hypertrophy(BPH)","RECRUITING","2025-02-17",{"date":66,"type":38},"2025-02-21",{"date":68,"type":38},"2024-03-14",{"date":70,"type":21},"2025-05",{"name":72,"class":45},"Sechenov University",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":46},"100470069","phase-2-proof-of-concept-study-to-evaluate-the-safety-and-efficacy-of-tryptophan-in-patients-with-bph-100470069","NCT05401032","Proof-of-concept Study to Evaluate the Safety and Efficacy of Tryptophan in Patients with BPH.","TryptoBPH - Proof-of-concept Study to Evaluate the Safety and Efficacy of Tryptophan in Patients with BPH","TryptoBPH","Inclusion Criteria:\n\n* Written informed consent;\n* Male patients with BPH for which tamsulosin is the therapeutic option per SoC;\n* Aged ≥50 and less than 75 years old;\n* With prostate volume ≥30 cm3 by TRUS;\n* Diagnosed with LUTS defined by a stable IPSS total score ≥13 points.\n\nExclusion Criteria:\n\n* Patients with post-void bladder residual volume ≥250 ml;\n* Patients with intravesical obstruction from any cause other than BPH;\n* History of any procedure considered an intervention for BPH;\n* Patients with active urinary tract infection;\n* History of recurrent urinary tract infections;\n* Current prostatitis or diagnosis of chronic prostatitis;\n* History of prostate or invasive bladder cancer;\n* Use of 5 α-reductase inhibitors within 6 months;\n* Phytotherapy within 2 weeks before entry;\n* Use of serotonin reuptake inhibitors or monoamine oxidase inhibitors;\n* Patients with acute or chronic kidney failure;\n* Patients with diagnosed or suspicion of intolerance to lactose;\n* Patients submitted to general anesthesia in the past 4 weeks;\n* Known intellectual disability that may hampers giving informed consent and would make the patient inappropriate for entry into this study, in the judgment of the investigator.","50 Years","74 Years",{"count":84,"type":21},70,[86],"PHASE2","Benign prostatic hyperplasia (BPH) is one of the most prevalent human diseases and a major cause of lower urinary tract symptoms (LUTS). Some men respond to current medical treatment (mainly α-1 adrenoreceptor antagonists and 5 α-reductase inhibitors), but a large proportion of patients continues to need a surgical procedure to treat resistant LUTS or even more serious complications of BPH, creating the emerging necessity for novel pharmacological therapies.\n\nOxitriptan may have a possible positive effect on BPH associated symptoms with probably no impact in sexual function (which is a common side effect of the current drugs for BPH associated symptoms). Also, improvement in symptoms could be higher than that of current drugs used for this condition.\n\nThis is a single-center parallel group, randomized clinical trial. The study will take place in Hospital de Braga (Urology department). Eligible patients will be randomized to receive tamsulosin 0.4mg (once a day, q.d.) or 5-HTP (5-hidroxitriptophan) 100mg (three times a day, t.i.d.), for 6 months.",[89,28],"BPH",[89,91,92,93,94],"LUTS","5-HTP","Oxitriptan","Tamsulosin","2025-01-03",{"date":97,"type":38},"2025-01-06",{"date":99,"type":38},"2024-12-20",{"date":101,"type":21},"2026-12-31",{"name":103,"class":45},"Clinical Academic Center (2CA-Braga)"]